DrugPatentWatch Database Preview
Details for Patent: 10,172,861
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 10,172,861 protect, and when does it expire?
Patent 10,172,861 protects VITRAKVI and is included in two NDAs.
This patent has sixteen patent family members in sixteen countries.
Summary for Patent: 10,172,861
| Title: | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| Abstract: | A novel crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim- idin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim- idin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form. |
| Inventor(s): | Arrigo; Alisha B. (Boulder, CO), Juengst; Derrick (Boulder, CO), Shah; Khalid (South San Francisco, CA) |
| Assignee: | Array BioPharma Inc. (Boulder, CO) |
| Application Number: | 15/872,769 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Process; |
Drugs Protected by US Patent 10,172,861
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,172,861
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015346046 | Start Trial | |||
| Brazil | 112017010141 | Start Trial | |||
| Canada | 2967951 | Start Trial | |||
| Chile | 2017001249 | Start Trial | |||
| China | 107428760 | Start Trial | |||
| Costa Rica | 20170263 | Start Trial | |||
| European Patent Office | 3218380 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
